{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:30:39Z","timestamp":1782556239236,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.antiviral.2019.104693","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T20:08:26Z","timestamp":1576181306000},"page":"104693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection"],"prefix":"10.1016","volume":"174","author":[{"given":"Hong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.antiviral.2019.104693_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.antiviral.2019.104693_bib2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"Buti M2, Chan HLY. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104693_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104693_bib4","doi-asserted-by":"crossref","first-page":"ofy273","DOI":"10.1093\/ofid\/ofy273","article-title":"Correlation between tenofovir drug levels and the renal biomarkers RBP-4 and \u00df2M in the ION-4 study cohort","volume":"6","author":"Chan","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104693_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104693_bib6","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Risk evaluation of viral load elevation and associated liver disease\/cancer in HBV (REVEAL-HBV) study Group.Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.antiviral.2019.104693_bib7","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2165\/00003495-200363200-00007","article-title":"Adefovir dipivoxil: a review of its use in chronic hepatitis B","volume":"63","author":"Dando","year":"2003","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.antiviral.2019.104693_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12072-017-9797-y","article-title":"Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects","volume":"11","author":"Ding","year":"2017","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104693_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104693_bib10","series-title":"Adefovir Dipivoxil for the Treatment of Chronic Hepatitis B. NDA 21-449 Gilead Sciences, Foster City, Calif","author":"FDA Advisory Committee Briefing Document","year":"2002"},{"issue":"11","key":"10.1016\/j.antiviral.2019.104693_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.14686","article-title":"Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate","volume":"34","author":"Kaneko","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104693_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(06)80742-7","article-title":"Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study","volume":"44","author":"Lee","year":"2006","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104693_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3851\/IMP1510","article-title":"Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B","volume":"15","author":"Lee","year":"2010","journal-title":"Antivir. Ther."},{"issue":"44","key":"10.1016\/j.antiviral.2019.104693_bib14","article-title":"Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B","volume":"95","author":"Li","year":"2016","journal-title":"Medicine (Baltim.)"},{"issue":"3","key":"10.1016\/j.antiviral.2019.104693_bib15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol. Int."},{"issue":"9","key":"10.1016\/j.antiviral.2019.104693_bib16","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1128\/AAC.01566-05","article-title":"Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer","volume":"50","author":"Lin","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104693_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(06)80037-1","article-title":"Pharmacokinetics and pharmacodynamics of pradefovir, a liver-targeting prodrug of PMEA in HBV patients","volume":"44","author":"Lin","year":"2006","journal-title":"J. Hepatol."},{"issue":"23","key":"10.1016\/j.antiviral.2019.104693_bib18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104693_bib19","first-page":"177","article-title":"Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function","volume":"60","author":"Murakami","year":"2014","journal-title":"Minerva Gastroenterol. Dietol."},{"issue":"12","key":"10.1016\/j.antiviral.2019.104693_bib20","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.antiviral.2019.104693_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2003.10.050","article-title":"Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus","volume":"126","author":"Perrillo","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.antiviral.2019.104693_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.antiviral.2019.104693_bib23","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/S0149-2918(03)90093-2","article-title":"Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection","volume":"25","author":"Qaqish","year":"2003","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104693_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7869\/tg.158","article-title":"Serum cholinesterase is an excellent biomarker of liver cirrhosis","volume":"35","author":"Ramachandran","year":"2014","journal-title":"Trop. Gastroenterol."},{"issue":"7","key":"10.1016\/j.antiviral.2019.104693_bib25","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/QAD.0b013e32833202e2","article-title":"Impairment in kidney tubular function in patients receiving tenofovir is associated with highertenofovir plasma concentrations","volume":"24","author":"Rodr\u00edguez-N\u00f3voa","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.104693_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2014.01.009","article-title":"Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment","volume":"103","author":"Wang","year":"2014","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104693_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/jcpt.12259","article-title":"Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil","volume":"40","author":"Wang","year":"2015","journal-title":"J. Clin. Pharm. Ther."},{"issue":"6","key":"10.1016\/j.antiviral.2019.104693_bib28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/apt.14497","article-title":"Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B","volume":"47","author":"Wong","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104693_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.03.004","article-title":"Global liver disease burdens and research trends: analysis from a Chinese perspective","volume":"71","author":"Xiao","year":"2019","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.antiviral.2019.104693_bib30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650698","article-title":"Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial","volume":"201","author":"Zolopa","year":"2010","journal-title":"J. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219305005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219305005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:30Z","timestamp":1759062690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219305005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"alternative-id":["S0166354219305005"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104693","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104693"}}